Biotech Stocks to Watch Amid Market Shifts
Tech is sliding into the weekend. Nasdaq futures are down over 1% and Japan's Nikkei fell 5% overnight.
But biotech is moving the other way this morning. A takeover report and a cancer trial win are doing the talking.
Here are 3 worth researching. 👇
📌 The Watchlist
1. Insmed | $INSM: Makes respiratory drugs Brinsupri and Arikayce. Bloomberg reported Thursday that Sanofi is weighing a takeover, possibly the biggest biopharma deal since Pfizer's $43 billion Seagen buy in 2023. Shares jumped 20.6% Thursday to $144.46.
2. Sanofi | $SNY: The would-be buyer, hunting for growth before its Dupixent blockbuster loses patent protection around 2030. Dupixent sales rose nearly 35% to 5.7 billion euros in the third quarter, close to 40% of Sanofi's revenue. Its shares fell about 2% Thursday on the report.
3. Merck | $MRK: Announced Friday its Phase 3 TroFuse-015 trial met its survival goal in advanced stomach and esophagus cancer, the first TROP2 drug to show a survival benefit in this setting. The trial enrolled 473 patients who had already tried two or more treatments. Shares slipped about 3% after the news, with a missed secondary goal in focus.
📌 The Part Worth Saving
A takeover report is a reason to research a stock. It is not a reason to buy blindly.
Look for:
- Whether the buyer confirms the talks, and at what price
- Real revenue behind the target, not just a pipeline story
- What the buyer gives up to pay for it
- Trial results with full data, not just a headline win
The best question: If the deal never happens, would you still want to own the target at today's price?
Education only, not financial advice.